Bachem expands multi-site production capacities to meet rising demand

The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland

Ichnos Glenmark Innovation’s full dose-escalation data show high response rates of ISB 2001

Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion

Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio

Merck KGaA, Darmstadt, Germany, Showcases Innovation at ASCO 2025

Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025

AstraZeneca's enhertu improved pCR in early-stage breast cancer

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care

Ichnos Glenmark Innovation receives USFDA fast track designation for ISB 2001 for relapsed/refractory multiple myeloma

IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma

CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA

Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein

Zynext Ventures invests in Feldan Therapeutics to drive innovation in intracellular drug delivery

Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities

CuraTeQ Biologics completes Phase 1 Pharmacokinetics study of biosimilar Denosumab

This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets

Plex Research partners With Ginkgo Bioworks on AI powered drug discovery to identify novel disease mechanisms

Findings likely to generate hypotheses about potential new uses of drugs